Trial record 12 of 31 for:
"Encephalitis, Tick-Borne"
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
This study has been completed.
Sponsor:
Baxter Healthcare Corporation
Information provided by:
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT00161954
First received: September 8, 2005
Last updated: October 19, 2006
Last verified: October 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.
| Condition | Intervention | Phase |
|---|---|---|
|
Encephalitis, Tick-Borne |
Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years |
Resource links provided by NLM:
Further study details as provided by Baxter Healthcare Corporation:
Eligibility| Ages Eligible for Study: | 16 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Understanding the nature of the study, agreement to its provisions and written informed consent
- Written informed consent of subject´s parents / legal guardians (if subject is under 18 years of age)
- Aged >= 16 years (from the 16th birthday) to <= 65 years (to the last day before the 66th birthday)
- Clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial)
- Negative pregnancy test result at the first medical examination (if female and capable of bearing children)
- Agreeing to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
- Agreeing to keep a subject diary.
Exclusion Criteria:
- History of any previous TBE vaccination
- History of TBE infection
- History of infection with other flaviviruses
- History of vaccination against yellow fever and/or Japanese B-encephalitis
- History of allergic reactions, in particular to one of the components of the vaccine
- Suffering from a disease (e.g. autoimmune disease) or undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions
- Known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages)
- Donation of blood or plasma within one month of study start
- Having received a blood transfusion or immunoglobulins within one month of study entry
- HIV positivity (an HIV test is not required specifically for the purpose of this study
- Simultaneous participation in another clinical trial including administration of an investigational product
- Participating in any other clinical study within six weeks prior to study start
- Participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies)
- Pregnancy or lactation (if female)
- Having received any other vaccination within two weeks prior to study entry
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00161954
Locations
| Belgium | |
| SGS Biopharma Research Unit Stuivenberg | |
| Antwerp, Belgium, 2060 | |
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
| Principal Investigator: | Baxter BioScience Investigator | Baxter BioScience |
More Information
No publications provided by Baxter Healthcare Corporation
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00161954 History of Changes |
| Other Study ID Numbers: | 225 |
| Study First Received: | September 8, 2005 |
| Last Updated: | October 19, 2006 |
| Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines |
Keywords provided by Baxter Healthcare Corporation:
|
Tick-Borne Encephalitis |
Additional relevant MeSH terms:
|
Encephalitis, Tick-Borne Encephalitis Central Nervous System Viral Diseases Virus Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections |
Encephalitis, Arbovirus Arbovirus Infections Tick-Borne Diseases Encephalitis, Viral RNA Virus Infections Flavivirus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on May 16, 2013